ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Brain Tumors

Brain Tumors

The US Food and Drug Administration granted the “breakthrough therapy” designation to a recombination poliovirus/rhinovirus conjugate known as PVS-RIPO, for treatment of recurrent glioblastoma multiforme.

Combined temozolomide and radiotherapy offer significantly better overall survival than radiotherapy alone in patients with glioblastoma multiforme (GBM) who undergo biopsy only rather than surgical resection.

This review will discuss examples of clinical applications of tumor and germline genomic testing for children with central nervous system (CNS) tumors, as well as promising investigative strategies.

One recurring theme from genomic studies of pediatric CNS tumors (and almost all cancers, for that matter) is that tumors that historically appeared to be a single entity based on examination under the microscope and routine immunohistochemical staining actually harbor molecularly distinct subgroups when analyzed by genomic sequencing techniques.

The aggressive management of brain metastases with SRS has supplanted radiation therapy in an effort to maintain patient quality of life in an era of advancing systemic cancer options.

Until prospective randomized clinical data accrue and mature, this controversial issue will continue to suffer from overinterpretation of inadequate supporting data.

The combination of chemotherapy and radiation therapy resulted in longer overall survival than radiation alone in certain patients with grade 2 gliomas, according to long-term results from a randomized trial.

Pages

Subscribe to Brain Tumors on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.